Maxygen, Inc. (NASDAQ:MAXY)

CAPS Rating: 4 out of 5

A biotechnology company committed to the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions.

Recs

0
Player Avatar dollarvaluemenu (39.12) Submitted: 1/11/2012 2:03:32 PM : Outperform Start Price: $5.57 MAXY Score: +3.65

value

Featured Broker Partners


Advertisement